Search

Your search keyword '"Ulrike Lambertz"' showing total 2 results
Start Over Author "Ulrike Lambertz" Publisher wiley
2 results on '"Ulrike Lambertz"'

1. ISEV position paper: extracellular vesicle RNA analysis and bioinformatics

Author

Andrew F. Hill, D. Michiel Pegtel, Ulrike Lambertz, Tommaso Leonardi, Lorraine O'Driscoll, Stefano Pluchino, Dmitry Ter-Ovanesyan, and Esther N.M. Nolte-‘t Hoen

Subjects
extracellular vesicles, deep sequencing, evRNA, RNA, bioinformatics, Cytology, QH573-671
Abstract

Extracellular vesicles (EVs) are the collective term for the various vesicles that are released by cells into the extracellular space. Such vesicles include exosomes and microvesicles, which vary by their size and/or protein and genetic cargo. With the discovery that EVs contain genetic material in the form of RNA (evRNA) has come the increased interest in these vesicles for their potential use as sources of disease biomarkers and potential therapeutic agents. Rapid developments in the availability of deep sequencing technologies have enabled the study of EV-related RNA in detail. In October 2012, the International Society for Extracellular Vesicles (ISEV) held a workshop on “evRNA analysis and bioinformatics.” Here, we report the conclusions of one of the roundtable discussions where we discussed evRNA analysis technologies and provide some guidelines to researchers in the field to consider when performing such analysis.

Published
2013
Full Text
View/download PDF

2. Short communication: High prevalence of the cytochrome P450 2C8*2 mutation in Northern Ghana

Author

Ulrike Lambertz, Andreas Pfützner, Frank P. Mockenhaupt, Alexander Weise, Susanne Röwer, Thomas Forst, Rowland N. Otchwemah, and Ulrich Bienzle

Subjects
business.industry, Public Health, Environmental and Occupational Health, Wild type, Amodiaquine, Pharmacology, medicine.disease, chemistry.chemical_compound, Infectious Diseases, chemistry, Artesunate, Chloroquine, medicine, Parasitology, Adverse effect, CYP2C8, business, Allele frequency, Malaria, medicine.drug
Abstract

Recently, Ghana has changed the first-line treatment of uncomplicated malaria from chloroquine to amodiaquine (AQ) plus artesunate. AQ may cause adverse events such as agranulocytosis and hepatoxicity. The pro-drug AQ is transformed by cytochrome P450 CYP2C8 to the active metabolite N-desethylaminodiaquine. Several polymorphic variants of CYP2C8 are known, some with reduced activity. In 200 randomly selected children from Northern Ghana, we determined the allele frequencies of the CYP2C8 variants CYP2C8*1 (wild type), CYP2C8*2, CYP2C8*3, and CYP2C8*4. We did not detect CYP2C8*3 and CYP2C8*4, but CYP2C8*2 showed an allele frequency of 0.1675. AQ metabolism in patients with CYP2C8*2 may be impaired, and with an increase of AQ based treatment the risk of severe adverse events may mount.

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results